RxDoctor Payments Data

Pamela Wheat

Nurse Practitioner · Springfield, MONPI 1952408262

Payments from drug & device makers

$1,197in general payments, 2019–2025

Across 45 payments — averaging $26.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$211
  • Otsuka America Pharmaceutical, Inc.$210
  • Teva Pharmaceuticals USA, Inc.$178
  • Axsome Therapeutics, Inc.$150
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$131
  • Neurocrine Biosciences, Inc.$84
  • plus $233 from 5 others

What the payments were for

  • Food & beverage$1,04687%
  • Education$15013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,197 in reported general payments places this provider in the 75th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$11,105
Medicare patients
57
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine56$363,715
IngrezzaValbenazine Tosylate28$231,088
VraylarCariprazine Hcl73$109,686
RexultiBrexpiprazole63$94,592
Invega SustennaPaliperidone Palmitate39$93,026
TrintellixVortioxetine Hydrobromide77$44,323
Lurasidone Hcl75$30,190
Risperdal ConstaRisperidone Microspheres27$24,485
Abilify MaintenaAripiprazole11$22,334
Aripiprazole189$16,577
Seroquel XrQuetiapine Fumarate12$15,056
BelsomraSuvorexant25$11,073
Paliperidone ErPaliperidone17$6,511
Venlafaxine Hcl ErVenlafaxine Hcl185$5,503
Bupropion XlBupropion Hcl332$5,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$178$363,71556 claims
Neurocrine Biosciences, Inc.Ingrezza$84$231,08828 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$58$117,51166 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$210$116,92674 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →